

01 FEB 12 PM 1:55

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Aventis Phaxma AG			
2. Address <input type="checkbox"/> Check if different than previously reported 801 Pennsylvania Avenue, NW, Suite 725			
3. Principal Place of Business (If different from line 2) City: Washington State/Zip (or Country) DC 20004			
4. Contact Name Eddie D. Evans		Telephone 202-898-3182	5. Senate ID # 56838-12
7. Client Name <input checked="" type="checkbox"/> Self		E-mail (optional)	6. House ID # 35186000

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) ☐ OR Year End (July 1-December 31) ☒

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ Termination Date \_\_\_\_\_

11. No Lobbying Activity ☐

<b>INCOME OR EXPENSES - Complete Either Line 12 OR Line 13</b>	
<b>12. Lobbying Firms</b> INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> \$ _____ Income (nearest \$20,000) Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	<b>13. Organizations</b> EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> \$ 860K Expenses (nearest \$20,000) <b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options. <input type="checkbox"/> Method A. Reporting amounts using LDA definitions only <input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature \_\_\_\_\_  
Printed Name and Title Eddie D. Evans, Vice President, Federal Government Affairs

Registrant Name Aventis Pharma AG Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

H.R. 4149 - Medicare Drug Coverage Preservation Act of 2000

H.R. 2892 - Access to Innovation for Medicare Patients Act of 1999

All provisions relating to self injectable biologics.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

House of Representatives and Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	Nov
Judy Cook		<input type="checkbox"/>
Eddie D. Evans		<input type="checkbox"/>
Donald Zowader		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None  
Aventis SA is the parent company of Aventis Pharmaceuticals. Aventis Pharmaceuticals is interested because the current practice by the agency unfairly penalizes patients who use Aventis products. This legislation clarifies Congressional intent regarding this matter.

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title Eddie D. Evans, VP, Federal Government Affairs

Registrant Name Aventis Pharma AG Client Name SELF

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues  
H.R. 4680 - Medicare Rx 2000 Act

All provisions relating to a prescription drug plan.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

House of Representatives and Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Judy Cook		<input type="checkbox"/>
Eddie D. Evans		<input type="checkbox"/>
Donald Zowader		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Aventis SA is the parent company to Aventis Pharmaceuticals. Aventis Pharmaceuticals worked with Congress to create an awareness for the need for comprehensive medicare reform, and the need to provide access, through the private marketplace, to those individuals that do not have coverage for prescription drugs.

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title Eddie D. Evans, VP, Federal Government Affairs

Registrant Name Aventis Pharma AG Client Name self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

H.R. 4461 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2001

H.R. 3240 - Drug Import Fairness Act of 2000

S. 2520 - Medicare Equity and Drug Safety Act of 2000

All provisions relating to the reimportation of prescription drugs.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

Senate and House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Judy Cook		<input type="checkbox"/>
Eddie D. Evans		<input type="checkbox"/>
Donald Zowader		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Aventis SA, headquartered in Strasbourg France is the parent company of Aventis Pharmaceuticals. Aventis Pharmaceuticals is interested because of the potentially negative effect this legislation could have on public health.

Signature Eddie D. Evans Date 2/9/01

Printed Name and Title Eddie D. Evans, VP, Federal Government Affairs

Registrant Name Aventis Pharma AG Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

H.R. 5178 - The Needlestick Safety and Prevention Act

All provisions relating to safe needles and prevention of needlesticks.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

House of Representatives and Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Donald Zowader		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Aventis Pharmaceuticals is interested to ensure that this legislation does not require the removal of injectable medical devices from the market abruptly.

Signature Eddie D. Evans Date 2/9/01

Printed Name and Title Eddie D. Evans, VP, Federal Government Affairs